ABSTRACT
In the modern era, cancer therapy often employs profoundly myelosuppressive chemotherapy in an effort to achieve a maximum antitumor effect. 1 Patients are therefore supported through periods of cytopenia with the intent of minimizing toxicity. Successful management requires a detailed understanding of the most frequently encountered complications and appropriate early therapeutic intervention designed to minimize morbidity. With regard to these basic principles, many of the improvements in outcomes for diseases such as acute leukemia can be directly traced to advances in supportive care. 2 The ability to support a myelosuppressed patient is dependent on a full-service blood bank that can provide immediate access to blood products. Although physiological requirements of individual patients may vary, the hemoglobin level is generally maintained at or above 8 g/dL. Patients with comorbidities, such as pulmonary disorders or coronary heart disease, may require more aggressive transfusional support. Hemorrhage and reduction in the platelet count below 5 to 10 × 10 9 /L have been shown to have a direct relationship. 3 The prophylactic use of platelet transfusions to prevent spontaneous hemorrhage has become the standard of care [4] [5] [6] and has had a significant impact on the incidence of hemorrhagic death. Standard guidelines have evolved such that patients with uncomplicated thrombocytopenia can be transfused when the platelet count falls below 10 × 10 9 /L. 7 Patients who are febrile or have other medical conditions that increase the risk of hemorrhage may require a higher transfusion threshold. More recently, a transfusion "trigger" of 5 × 10 9 /L has been suggested, citing clinical data to support this practice. 8, 9 However, there is concern about the accuracy and precision of automated platelet-counting methods, which often deteriorate when the count falls below 20 × 10 9 /L. 10 Therefore, the ability of the laboratory to deliver accurate information to the clinician is of the utmost importance for proper management. The current generation of automated hematology analyzers mostly employs electronic impedance (ie, Beckman Coulter, Brea, CA; Sysmex, Mundelein, IL; and Abbott, Santa Clara, CA) or optical light scatter (ie, Sysmex; Siemens, Tarrytown, NY; and Abbott) technology for platelet enumeration. [11] [12] [13] [14] [15] [16] [17] [18] These methods generally provide precise and accurate platelet counts in healthy subjects. 19 However, multiple investigators have reported inaccuracies in platelet measurements in the setting of thrombocytopenia. [20] [21] [22] [23] [24] [25] Biases are often due to failure of the instrument to discriminate platelets from interferences (nonplatelet particles), such as cell fragments or debris, which result in a spuriously high platelet count. [22] [23] [24] Conversely, large platelets may exceed the analytical upper threshold of what is classified as platelets, leading to a falsely decreased count. 26 As discussed above, such an error in platelet assessment has clinical implications in that overestimation may not prompt the clinician to prescribe a transfusion, whereas one would have been administered had an accurate count been reported. 21, 25 Given the above considerations, we undertook a prospective study comparing the accuracy of various technologies used in enumerating platelets commonly found on commercially available hematology analyzers. The study was conducted in a defined population of patients with cancer with the intent of exploring differences in platelet counts obtained by the various methods. We also determined the potential impact that differences observed in patients with severe thrombocytopenia might have in the decision to transfuse platelets at the time of analysis. Potential confounding phenomena, such as the presence of red blood cell abnormalities that could interfere with platelet measurements, were also examined in a subset of patients. The results of this study are presented below.
Materials and Methods

Patient Samples and Measurements
A total of 403 EDTA-anticoagulated residual samples from patients with hematologic malignancies and platelet counts of 50 × 10 9 /L or less were selected from the routine workload of the main hematology laboratory at Memorial Sloan-Kettering Cancer Center (MSKCC). All patients included in the study had previously provided informed consent for specimen analysis. This study was approved by the institutional review board at MSKCC. Samples were split and tested within eight hours of collection using two opticalbased platelet-counting methods-Advia 2120i (Siemens) and CELL-DYN Sapphire (Abbott)-and the CD61 immunoplatelet (CD61) method (Abbott) performed on the Sapphire. After the study was under way, a third analyzer became available, the Sysmex XE-2100 (Sysmex), and 127 of the 403 samples were also processed and reported by the Sysmex impedance and optical platelet-counting methods. Power calculations were performed for each instrument comparison and showed that sample sizes of 18 to 184 were required to detect a difference of 0.6 to 9.2 with a power of 80%. In each case, the numbers of samples used exceeded minimum requirements. To assess method precision, a sample with a normal platelet count and morphology was diluted with saline to obtain a platelet count of approximately 10 × 10 9 /L. The sample was split and run 22 times by each method.
Phase Microscopy
Thirty-six samples with platelet counts of 4 to 570 × 10 9 /L were selected from the routine workload and analyzed in duplicate using phase microscopy. Whole blood was diluted with the Leukochek device (Biomedical Polymers, Gardner, MA), and platelets were counted manually using the procedure developed by Brecher and Cronkite. 27 The specimens were split at the time of analysis and simultaneously measured by the CD61 method on the Sapphire.
Automated Blood Analyzers
Siemens Advia 2120i
Optical platelet count. The Advia 2120i enumerates platelets using a dual-angle optical light scatter method. Volume and refractive index are measured on isovolumetrically sphered platelets using low-angle (2°-3°) and high-angle (5°-15°) light scatter. Platelet volume (1-30 fL) and refractive index (1.35-1.44) are derived from the Mie theory of light scattering for homogeneous spheres.
Abbott CELL-DYN Sapphire
Optical platelet count. Isovolumetrically sphered platelets are hydrodynamically focused through the Sapphire flow cell, where laser light scatter is collected at two angles, 90° and 7°, which measure platelet complexity and density, respectively.
Immunofluorescence analysis (CD61 immunoplatelet count). The immunoplatelet count uses a monoclonal antibody conjugated to a fluorochrome, fluorescein isothiocyanate (BD Biosciences, San Jose, CA) in a lyophilized pellet at the bottom of a unique 12 × 75-mm K-Resin tube (Becton Dickinson, Franklin Lakes, NJ). CD61 is specific for glycoprotein IIIa on the platelet membrane. Light scatter at 90° and 7° and green fluorescence (530 nm) are collected, with software algorithms producing a platelet count without operator intervention.
Sysmex XE-2100
Optical platelet count. Platelets are counted using a fluorescent dye in the reticulocyte channel. Forward light scatter and lateral fluorescence detection signals are plotted in a twodimensional scattergram. Multiple discriminators are used to separate reticulocytes from platelets.
Impedance method. Hydrodynamically focused platelets pass through the aperture of an impedance transducer, generating a one-dimensional impedance pulse that correlates with particle size. The events are plotted in a distributional-size histogram. Three threshold discriminators are used to capture the platelet population.
Statistics
Intrameasurement precision on each instrument was determined by analysis of mean, standard deviation, and coefficient of variation (CV). Other statistical analysis was performed using Analyse-It (Leeds, UK). Methods were compared using standard linear regression statistics, and systemic error (bias) was demonstrated with difference plots and associated t test statistics to determine the significance of the difference between methods. The conservative Bonferroni correction procedure was used to adjust for multiple comparisons. To estimate the clinical impact of falsely increased and decreased platelet counts, we compared the number of transfusion indications at various platelet count thresholds as determined by the test methods, with potential transfusion decisions made using the CD61 reference method.
Results
Comparison of Phase Microscopy and CD61 Immunoplatelet Count
Published reports have shown the performance of the CD61 method to be equivalent in accuracy and more precise compared with the flow cytometric reference method. 28, 29 For the purpose of this study, we validated CD61 as a surrogate reference method using a select number of samples (n = 36). The results showed good agreement between CD61 and the reference manual phase platelet counts, as shown in ❚Figure 1❚: r = 0.993 (y = 0.95x -2.6). These results are consistent with the findings of a similar study performed by Gill and colleagues, 30 who also compared CD61 with manual phase microscopy counts: r = 0.980 (y = 0.92x -0.60).
Precision Study of the Analyzers
Precision studies of the three hematology analyzers were undertaken for the degree of thrombocytopenia seen in this study. The mean, standard deviation, and CV for the optical and impedance measurements on the various analyzers are shown in ❚Table 1❚. Method imprecision ranged from 2.6% to 8.1% at a platelet count of approximately 10 × 10 9 /L. The immunoplatelet count showed the lowest CV percentage when comparing the different methodologies.
Comparison of Measuring Degrees of Thrombocytopenia Among Analyzers
As described above, platelet measurements were compared across the three analyzers, as well as the different An increase in proportional error is evident in the 10 × 10 9 /L or less group. An increase in the slopes and decreases in the correlation coefficients suggest a deterioration in analyzer performance at platelet counts of 10 × 10 9 /L or less. The clinical significance of these determinations is especially evident in ❚Table 4❚, which shows a progressive increase in the rate of undertransfusion as the platelet count thresholds decrease.
Effect of Platelet Measurement on Transfusion Decision and Timing of Transfusion
Accurate enumeration of the platelet count has the potential to affect clinical intervention. Given the current "trigger" values for the administration of platelet transfusions currently in use as standard of care, disparity in the count reported by an analyzer and the "true" count, as determined by a reference method, may result in either undertransfusion (reference ≤10, reported value >10) or overtransfusion (reference >10, reported value ≤10) of platelets. The potential for underprescribing platelet transfusions, given the measurements obtained by various methods/analyzers using decision thresholds of 50, 30, 20, and 10 (×10 9 /L) or less, is outlined in ❚Table 5❚ and ranges from 9.1% to 22.4% in the 20 × 10 9 /L group and 30.5% to 43.3% in the 10 × 10 9 /L group. The risk for overtransfusion ranges from 0% to 6.1%. To better understand the clinical significance of biased platelet counts among analyzers in severe thrombocytopenia, we investigated the undertransfusion rates at transfusion triggers of 5 × 10 9 /L or less to 15 × 10 9 /L or less. As shown in Table 4 , in all four platelet-counting methods, the potential for decision errors dramatically increased as the threshold was lowered. The Abbott optical method was associated with the lowest error rate, followed by Siemens optical and Sysmex impedance, which were fairly consistent at each threshold. The Sysmex optical method demonstrated the highest potential for undertransfusion.
The medical records of 31 patients with optical platelet counts of more than 10 × 10 9 /L and CD61 counts of 10 × 10 9 /L or less were reviewed to determine if a transfusion had been administered. In 20 (64.5%) of 31 patients, prophylactic transfusions were administered within 24 hours of the platelet count being reported, despite an optical measurement of more than 10 × 10 9 /L. The remaining 11 (35.5%) of 31 patients were eventually transfused outside of 24 hours and, in most cases, only after a subsequent optical platelet count of 10 × 10 9 /L or less had been reported. The study design did not include prospective monitoring of individual patients' clinical status, and therefore it is not known if any of the undertransfused patients experienced any significant hemorrhage.
Discussion
This study was designed to evaluate the accuracy and precision of contemporary automated platelet-counting methods in patients with cancer who have associated thrombocytopenia. Our findings of inaccuracies when using optical and impedance platelet counts are consistent with prior reports. [23] [24] [25] [26] 31 In addition, the percentage of severely thrombocytopenic patients who may not have received a needed transfusion because of falsely elevated platelet counts was higher than in most previous reports.
The potential effect on transfusion decisions demonstrated in this study is, to our knowledge, one of the largest reported to date. More than 40% of patients who are transfusion eligible may indeed not be receiving one if strict guidelines are followed and optical/impedance methods are used. The risk of undertransfusion greatly increased as the threshold was lowered below 10 × 10 9 /L, and the error rate differed depending on the analyzer/method used in the platelet determination. Based on these data, lowering the platelet threshold to 5 × 10 9 /L or less may be problematic given the technical issues reported above. CI, confidence interval. In an attempt to further examine the potential cause(s) for the falsely increased platelet counts seen in this study, peripheral blood smears were retrieved in 10 discrepant cases in which the CD61 counts were less than 10 × 10 9 /L. In most of the smears examined, there were no appreciable numbers of RBC fragments, microcytes, WBC cytoplasmic fragments, or other nonplatelet particles that may have falsely elevated the automated platelet counts.
We believe that this study is important because it introduces the accuracy of measuring low platelet number as a variable for consideration at a time when large studies are appearing in the literature that advocate using either no or lower prophylactic transfusion triggers in distinct subpopulations of patients with severe thrombocytopenia. 32 This study is extensive in that it presents one of the largest data sets to address this question in a prospective manner. In addition, there is clinical correlation for a subset of patients as to the timing of the platelet transfusion as a response to the laboratory-based trigger. The study was performed at a major tertiary care center where thrombocytopenia is relatively common. Many of the patients at MSKCC are transfusion eligible, and while a trigger of 10 × 10 9 /L or less has been recommended, decision algorithms used by clinicians can vary, and the data appear to support this. Furthermore, it is unlikely that these decisions are made in light of understanding the potential for inaccuracy in the platelet count. The biases we found have potential clinical implications since the standards for platelet transfusion are undergoing revision. Because of this, we believe it is important to introduce this as a potential confounder and help provide a critical assessment of how the laboratory triggers, which form the basis of clinical care, are generated.
Clinical laboratories (and those who design and develop instrumentation) strive to produce automated platelet counts that are both accurate and precise throughout the reportable range of the analyzer. This presents a problem in severely thrombocytopenic samples since it has been demonstrated that clinically significant biases may affect decisions regarding when to administer platelet transfusions. What, then, are the alternatives? Laboratories could shift to an alternate method when faced with these problematic samples. The manual phase platelet count, while recognized as the gold standard for the past 50 years, is not a feasible alternative because it is time-consuming, resource draining, and technically difficult, and it suffers from very poor precision. Should laboratories report a platelet count obtained through smear estimation? While this may be a quick and easy alternative, it is neither accurate nor precise. 33 Such problems generally prohibit its use except to estimate a platelet count as decreased, normal, or increased. Immunologic plateletcounting methods based on flow cytometric quantitation of platelets labeled with anti-CD41 and CD61 have proven to be extremely accurate and reproducible, even in severely thrombocytopenic samples. 34, 35 It has been suggested that the immunologic platelet count is a suitable alternative to optical and impedance methods in severely thrombocytopenic samples, especially when deciding whether a platelet transfusion should be administered. 28 Kunz et al 28 have suggested that platelet counts close to transfusion trigger thresholds should be verified with an immunologic method. Widespread adoption of immunologic methods of platelet determinations poses several important challenges. In many hospitals, the flow cytometry and hematology laboratories are physically separated from each other and operate independently. The flow cytometry laboratory would need to develop and implement CD41/61 immunoplatelet counting and incorporate it into its workflow. In a large cancer center setting, this added volume would be difficult to accommodate since the priority of the flow cytometry laboratory is the diagnosis and monitoring of hematologic neoplasms. Further complicating such a practice is that the turnaround times and logistics associated with transporting, processing, and reporting the flow cytometric platelet count may prove to be unacceptably long for clinicians needing to make quick decisions regarding patient assessment and treatment. Alternatively, an automated immunologic platelet count is currently available on one of the hematology analyzers tested in this study; however, the test cost is similar to immunophenotyping assays, processed as a separate test and not routinely done as part of the instrument's complete blood cell count.
Therefore, the laboratory may choose to be selective in determining which samples require specialized testing. With the immunoplatelet method, one can envision a "two-tiered" approach in which samples are initially screened with optical/impedance analyzers, and those patients who have been determined to have severe thrombocytopenia have the precise level verified by immunologic techniques. Further prospective studies may be required to determine whether such testing is clinically indicated for most patients with malignant disease.
